ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ObsEva SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

PALVELLA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing topical therapies for rare genetic skin diseases.
United States of America
PVLA
Pangen Biotech Inc. Logo
Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.
South Korea
222110
Pasithea Therapeutics Corp. Logo
Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.
United States of America
KTTA
Pelthos Therapeutics Inc. Logo
Biopharma with an approved gel for molluscum, advancing a nitric oxide-based pipeline.
United States of America
PTHS
Pentixapharm Holding AG Logo
Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.
Germany
PTP
PeopleBio, Inc. Logo
Develops blood tests for early diagnosis of neurodegenerative diseases like Alzheimer's.
South Korea
304840
PEPTONIC Medical AB Logo
Develops clinically proven self-care products for women's intimate health.
Sweden
PMED
Develops sustained-release peptide medicines for chronic & neurodegenerative disorders.
South Korea
087010
PERRIGO Co plc Logo
World's largest manufacturer of store-brand OTC consumer health products.
United States of America
PRGO
Perseus Proteomics Inc. Logo
Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.
Japan
4882

Talk to a Data Expert

Have a question? We'll get back to you promptly.